Acute Hepatitis C in a Contemporary US Cohort: Modes of Acquisition and Factors Influencing Viral Clearance

Wang, Chia C.; Krantz, Elizabeth M; Klarquist, Jared; Krows, Meighan; McBride, Lanamarie; Scott, Edward P.; Shaw-Stiffel, Thomas; Weston, Shiobhan R.; Thiede, Hanne; Wald, Anna; Rosen, Hugo R.

doi:10.1086/522608

Cited by 165 publications

(124 citation statements)

References 37 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…One important outcome is the attainment of a spontaneous resolution of viremia (viral clearance) 37, 38. Viral clearance is estimated to occur in approximately 20% of adults, while children have a slightly greater chance of viral clearance 61, 62, 63. In children with perinatal transmission, 25%‐40% may spontaneously undergo viral clearance, usually by age 2; this has been described as a resolution of neonatal HCV infection 4.…”

Section: Natural History Of Hcv Infection In Children and Adolescentsmentioning

confidence: 99%

Hepatitis C virus infection in children and adolescents

Squires

Balistreri

2017

Hepatology Communications

View full text Add to dashboard Cite

Section: Natural History Of Hcv Infection In Children and Adolescentsmentioning

confidence: 99%

Hepatitis C virus infection in children and adolescents

Squires

Balistreri

2017

Hepatology Communications

View full text Add to dashboard Cite

“…Epidemiological studies have shown that 46.2% of all hepatitis C cases are caused by HCV GT1, making GT1 the most prevalent genotype [3]. Even though most of the patients initially do not experience any symptoms, about 75% are not able to spontaneously clear the virus from the organism, and develop a chronic HCV infection [4]. HCV causes progressive liver injury in those patients, which in approximately 16% progress to liver cirrhosis and ultimately in 1-5%, within two decades from acute infection, to hepatocellular carcinoma.…”

Section: Clinical Background Of Hcv Infectionmentioning

confidence: 99%

Pharmacogenomic Testing in the Era of Patient-Tailored HCV Treatment

Smolić¹,

Omanović²,

Božić³

et al. 2017

Update on Hepatitis C

View full text Add to dashboard Cite

Hepatitis C affects approximately 180 million people worldwide, with 3-4 million newly infected each year. Hepatitis C virus (HCV) has been classified into seven different genotype categories, wherein HCV genotype 1 (HCV-1) is the most prevalent. To date, there is still no vaccine available against HCV infection. Until recently, combination therapy of pegylated interferon-a (PegIFN) and ribavirin (RBV) has been the standard of care. Nevertheless, for many patients, particularly those infected with HCV genotype 1 (HCV-1), this treatment has resulted with unsatisfactory treatment response rates and high adverse drug reaction (ADR) rates. Many clinical factors, including pharmacogenetics, influence the treatment response rate. This review focuses on the association between pharmacogenetics and HCV antiviral therapy in patients infected with HCV genotype 1 and other genotypes (GT); patients reinfected with HCV after liver transplantation; and patients coinfected with HCV and human immunodeficiency virus. Data considering triple therapy in HCV-infected patients are also reviewed. Additionally, various genetic polymorphisms, with an emphasis to IL-28B, and their association with pharmacogenetic testing in HCV are discussed.

show abstract

“…Vertical transmission is also possible and is more likely if the mother is HIV-positive. A more recent trend is the increase in the number of new cases of acute HCV in MSM who are HIV-positive acquired via sexual transmission (8,9).…”

Section: Viral Aetiologiesmentioning

confidence: 99%